Michal Vrablik (Czech Republic)
First Faculty of Medicine Charles University, General University Hospital in Prague Third Internal DepartmentAuthor Of 2 Presentations
Live Q&A (ID 1551)
O064 - Are risk-based LDL-C goals achieved in primary and secondary care in Central and Eastern Europe? Comparison with other Europe regions from the DA VINCI observational study (ID 1412)
Abstract
Background and Aims
Assess the proportion of patients in the Central and Eastern Europe (CEE) region achieving the risk-based LDL-C goals recommended by the 2016 and 2019 ESC/EAS guidelines. Compare with other Europe regions.
Methods
Data were collected at a single visit for adults who consented to participate, with any LLT in the past 12 months and an LDL-C measurement in the past 14 months. Primary outcome was LDL-C goal attainment ≥ 28 days after starting the most recent lipid lowering therapy (stabilized LLT).
Results
Out of 5888 total subjects, 2154 were enrolled from six CEE countries: Czech Republic, n=509; Hungary, n=319; Poland, n=460; Romania, n=259; Slovakia, n=123; Ukraine, n=484. Mean (SD) age, 64 (11) years; 48% female. Of 1476 subjects on stabilized LLT at LDL-C measurement, 664 (45%) were primary prevention and 812 (55%) secondary prevention. 53% were receiving moderate intensity statin monotherapy; 32% receiving high intensity statin monotherapy and 5% receiving ezetimibe combination therapy. Mean (SD) LDL-C was 97 mg/dL (2.5 mmol/L). 44% and 24% of patients achieved their risk-based LDL-C 2016 and 2019 goals, respectively. Goal attainment in the CEE region was lower than observed in Northern and Western Europe (Figure 1).
Conclusions
These data highlight a significant gap between guidelines and clinical practice for lipid management in the CEE region, with fewer than one-quarter of patients having LDL-C levels below the 2019 risk-based LDL-C goal. Risk-based goal attainment was lower than observed in Northern or Western Europe; combination therapy with non-statin LLT is needed to address this gap.
Presenter of 2 Presentations
Live Q&A (ID 1551)
O064 - Are risk-based LDL-C goals achieved in primary and secondary care in Central and Eastern Europe? Comparison with other Europe regions from the DA VINCI observational study (ID 1412)
Abstract
Background and Aims
Assess the proportion of patients in the Central and Eastern Europe (CEE) region achieving the risk-based LDL-C goals recommended by the 2016 and 2019 ESC/EAS guidelines. Compare with other Europe regions.
Methods
Data were collected at a single visit for adults who consented to participate, with any LLT in the past 12 months and an LDL-C measurement in the past 14 months. Primary outcome was LDL-C goal attainment ≥ 28 days after starting the most recent lipid lowering therapy (stabilized LLT).
Results
Out of 5888 total subjects, 2154 were enrolled from six CEE countries: Czech Republic, n=509; Hungary, n=319; Poland, n=460; Romania, n=259; Slovakia, n=123; Ukraine, n=484. Mean (SD) age, 64 (11) years; 48% female. Of 1476 subjects on stabilized LLT at LDL-C measurement, 664 (45%) were primary prevention and 812 (55%) secondary prevention. 53% were receiving moderate intensity statin monotherapy; 32% receiving high intensity statin monotherapy and 5% receiving ezetimibe combination therapy. Mean (SD) LDL-C was 97 mg/dL (2.5 mmol/L). 44% and 24% of patients achieved their risk-based LDL-C 2016 and 2019 goals, respectively. Goal attainment in the CEE region was lower than observed in Northern and Western Europe (Figure 1).
Conclusions
These data highlight a significant gap between guidelines and clinical practice for lipid management in the CEE region, with fewer than one-quarter of patients having LDL-C levels below the 2019 risk-based LDL-C goal. Risk-based goal attainment was lower than observed in Northern or Western Europe; combination therapy with non-statin LLT is needed to address this gap.